Short-term pullbacks and downward price volatility in TG Therapeutics stock are frequently driven by broader biotechnology sector rotations, profit-taking following periods of rapid upward momentum, and investor sensitivity toward commercial execution milestones for its core therapeutic portfolio. Market participants regularly weigh quarterly research and development expenditures against ongoing net sales trajectories for its flagship pharmaceutical products.